What's breaking now, across thousands of outlets.
Plus, news about GSK, Ascletis, BioMarin, Rigerna and Hisun. Ono Pharma’s endocannabinoid modulator flunks five trials: The biotech’s ONO-1110 did not meet the primary endpoint in five separate Phase 2 studies ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Random Acts of Flowers Indianapolis marked ten years of service, delivering its 175,000th flower arrangement to Eskenazi Health.
The Hill is thrilled to present the third annual “Bang for Your Buck: Get the Most from Your 2027 Medicare Benefits.” This year’s event is expanded in scope beyond prescription drug plans to address…
The findings could help scientists better understand the disease processes involved and identify potential targets for developing new therapies
How much exercise adults need each week, per the CDC: 10 points covering the 150-minute target, vigorous options, strength training and why some movement beats none
A sunny Sunday stroll with friends could help support someone facing diabetes. La Cala de Mijas will host its eighth […]
A major challenge in Congo is limited contact tracing and collaboration with affected communities; health workers sometimes spend more time trying to convince locals to work with them than giving care
